Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
Crossref DOI link: https://doi.org/10.1007/s10157-016-1299-z
Published Online: 2016-07-07
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Koiwa, Fumihiko
Terao, Akira
Funding for this research was provided by:
Kissei Pharmaceutical Co., Ltd
License valid from 2016-07-07